FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) submitted by Celgene Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myelofibrosis Post-essential Thrombocythemia
• Myelofibrosis Post-polycythemia Vera

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

SUPPL AP for INREBIC (FEDRATINIB HYDROCHLORIDE)